BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA‐PME), a
French company specializing in the development and manufacturing of
innovative medical and drug delivery devices, announces today that its
new device Onejet has won the Patient Safety and Convenience Award
attributed by Pharmapack Europe 2018.
Onejet is the first motor driven, disposable and Bluetooth connected
auto injector compatible with standard primary containers. Its
motorization can be adjusted to any biologics density, allowing Onejet
to easily deliver highly viscous drugs.
Injection data (time, doses and date) are transferred to a mobile app
via Bluetooth, allowing monitoring of key treatment information.
Connectivity is made possible thanks to an innovative and effortless
pairing system requiring a simple confirmation from patient.
Onejet enhances BIOCORP’s connected devices range designed for modern
healthcare. The global biologicals drugs market is increasing since
those drugs are used to treat chronic diseases such as cancer, severe
blood disorders and other auto immune diseases. Transparent Market
Research forecasts a 10% annual growth rate: the market was US$ 210
billion in 2016 and is relied to ascend to US$ 480 billion by 2024(1).
Onejet answers an unmet need of pharmaceutical companies requiring an
auto injection device flexible enough to deal with different containers
and viscosities, starting from the early clinical trials stage. Onejet
offers in a single mechanical platform an easy to use device, in a
compact design with the advanced functionalities of ‘’smart’’ platforms
including motor driven injection system, calibration of injection speed
and force, and connectivity.
‘’Our whole team is very proud of winning this third Pharmapack Award
in 4 years. Our connected injector pen Datapen was awarded in 2015 and
our smart sensor Easylog in 2016. It is today Onejet’s turn to be
rewarded during this major health exhibition. We are confident
that this device will bring to our pharma companies partners a new tool
for the safety and comfort of their patients’ treatments’’ commented
Eric Dessertenne, BIOCORP’s Deputy Chief Executive Officer.
ABOUT PHARMAPACK AWARDS
The Awards, launched alongside the
exhibition and conference in 1997, are a yearly returning highlight at
Each year, the most innovative exhibitors and
pharma companies compete to win these prestigious awards. The Awards are
judged by a panel of independent industry experts and are handed out
during the dedicated ceremony on the show floor.
Founded in 2004 in Issoire (near
Clermont-Ferrand), France, BIOCORP is a French company specializing in
the development and manufacturing of medical devices and innovative drug
delivery systems. It is listed as ‘Innovative Company’ by the French
public investment bank Bpifrance. With over twenty years of experience
and more than 30 manufactured products, BIOCORP is a key player in the
industry, providing drug delivery solutions that meet the evolving needs
of patients. Today, BIOCORP continues to innovate in medical plastics,
its core business, and to market traditional devices (alternative to
aluminum capsules, syringe and vial administration systems) that have
been an important source of recurring income. Its solid expertise and
capacity to innovate have allowed the company to develop new
Internet-connected products, including: the DataPen, a reusable smart
injection pen that automatically transmits data to a mobile app, helping
patients to manage their treatment; and treatment management add-ons,
which adapt to existing delivery devices and are compatible with most
injection pens in the market. The company has a team of 48 employees.
BIOCORP is listed on Alternext since July 2015 (FR0012788065 – ALCOR).
more information, please visit www.biocorpsys.com
us on Twitter @BIOCORPSystems
(1) source : https://www.transparencymarketresearch.com/pressrelease/global-biologics-market.htm).
View source version on businesswire.com: http://www.businesswire.com/news/home/20180207005032/en/